The FDA has started a priority review of Vertex Pharma and CRISPR Therapeutics’ exagamglogene autotemcel (exa-cel) in sickle cell disease (SCD), with a decision on approval due by 8th December.
Vertex Pharma and partner CRISPR Therapeutics ... The rolling application for exagamglogene autotemcel (exa-cel) – formerly known as CTX001 – will start in November, while a filing in Europe ...
HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...
Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.
BOSTON, December 08, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVYâ„¢ (exagamglogene autotemcel) from global clinical trials in people with ...
Hosted on MSN1mon
Gilead, Vertex initiated as new big biotech buys at CitiCiti has started coverage of Gilead Sciences (NASDAQ:GILD) and Vertex Pharmaceuticals ... β-thalassemia gene therapy Casgevy (exagamglogene autotemcel) -- which it is partnered with CRISPR ...
GlobalData on MSN2mon
Vertex shares up after full-year product revenue guidance boostVertex Pharmaceuticals has seen a 12% revenue ... cell therapy Casgevy (exagamglogene autotemcel). The company has now ...
Vertex Pharmaceuticals Inc.’s chief operating officer Stuart Arbuckle said during the Stifel Healthcare Conference in November that his firm’s launch last year of Casgevy (exagamglogene autotemcel) ...
BOSTON, December 08, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVYâ„¢ (exagamglogene autotemcel) from global clinical trials in people with severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback